Cediranib

Generic Name: Cediranib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₅H_₂₇FN_₄O_₃

CAS Number: 288383-20-0

Unique Ingredient Identifier: NQU9IPY4K9

Background: The novel indole-ether quinazoline Cediranib is a highly potent (IC < 1 nmol/L) ATP-competitive inhibitor of recombinant KDR tyrosine kinase in vitro. It is being developed clinically as a once-daily oral therapy for the treatment of cancer.

Indication: For the treatment of liver cancer, advanced non-small cell lung cancer (NSCLC), advanced colorectal cancer (CRC) and other solid tumors.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...

Phase 1

Active, not recruiting

Conditions: Colorectal Neoplasms
Breast Neoplasms

Interventions: Drug: Olaparib
Drug: Cediranib
Drug: Durvalumab

First Posted Date: 2015-06-29

Last Posted Date: 2025-01-07

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 257

Registration Number: NCT02484404

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 3

Active, not recruiting

Conditions: Ovarian Clear Cell Adenocarcinoma
Fallopian Tube Clear Cell Adenocarcinoma
Fallopian Tube Transitional Cell Carcinoma
Fallopian Tube Undifferentiated Carcinoma
Ovarian Endometrioid Tumor
Ovarian Seromucinous Carcinoma
Ovarian Serous Tumor
Ovarian Transitional Cell Carcinoma
Recurrent Fallopian Tube Carcinoma
Recurrent Ovarian Carcinoma

Interventions: Drug: Carboplatin
Procedure: Biospecimen Collection
Drug: Cediranib Maleate
Procedure: Computed Tomography
Procedure: Echocardiography
Drug: Gemcitabine
Drug: Gemcitabine Hydrochloride
Other: Laboratory Biomarker Analysis
Procedure: Magnetic Resonance Imaging
Drug: Olaparib
Procedure: Multigated Acquisition Scan
Other: Pharmacological Study
Other: Quality-of-Life Assessment
Drug: Paclitaxel
Drug: Pegylated Liposomal Doxorubicin Hydrochloride

First Posted Date: 2015-05-18

Last Posted Date: 2024-11-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 579

Registration Number: NCT02446600

Locations: 🇺🇸
Alaska Women's Cancer Care, Anchorage, Alaska, United States
🇺🇸
Atrium Health Navicent, Macon, Georgia, United States
🇺🇸
Legacy Mount Hood Medical Center, Gresham, Oregon, United States

and more 355 locations

Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer

Phase 2

Active, not recruiting

Conditions: Ovarian Carcinoma
Primary Peritoneal Carcinoma
Primary Peritoneal Serous Adenocarcinoma
Fallopian Tube Carcinoma
Fallopian Tube Endometrioid Adenocarcinoma
Fallopian Tube Serous Adenocarcinoma
Ovarian High Grade Endometrioid Adenocarcinoma
Ovarian High Grade Serous Adenocarcinoma
Primary Peritoneal Endometrioid Adenocarcinoma

Interventions: Procedure: Biopsy
Procedure: Biospecimen Collection
Drug: Cediranib Maleate
Procedure: Computed Tomography
Procedure: Echocardiography
Procedure: Magnetic Resonance Imaging
Procedure: Multigated Acquisition Scan
Drug: Olaparib
Other: Questionnaire Administration

First Posted Date: 2015-01-26

Last Posted Date: 2024-10-31

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 70

Registration Number: NCT02345265

Locations: 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸
NCI - Center for Cancer Research, Bethesda, Maryland, United States

and more 17 locations

A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib

Phase 2

Completed

Conditions: Ovarian Cancer

Interventions: Drug: Olaparib
Drug: Cediranib

First Posted Date: 2015-01-16

Last Posted Date: 2018-06-12

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 4

Registration Number: NCT02340611

Locations: 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Sunitinib or Cediranib for Alveolar Soft Part Sarcoma

Phase 2

Active, not recruiting

Conditions: Sarcoma, Alveolar Soft Part

Interventions: Drug: Cediranib
Drug: Sunitinib
Other: Prochlorperazine
Other: Promethazine
Other: Benzodiazepine
Other: Filgrastim
Other: Sargramostim
Other: Lomotil
Other: Loperamide
Other: Vitamin B6
Other: Aquaphor
Drug: Acetaminophen
Drug: Levothyroxine
Drug: Warfarin

First Posted Date: 2011-07-12

Last Posted Date: 2023-11-29

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 34

Registration Number: NCT01391962

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies

Phase 1

Active, not recruiting

Conditions: Refractory Malignant Solid Neoplasm
Stage IV Cutaneous Melanoma AJCC v6 and v7
Metastatic Melanoma
Unresectable Malignant Solid Neoplasm

Interventions: Drug: Cediranib
Drug: Cediranib Maleate
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Drug: Selumetinib
Drug: Selumetinib Sulfate

First Posted Date: 2011-06-02

Last Posted Date: 2024-07-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 19

Registration Number: NCT01364051

Locations: 🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States

Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel

Phase 2

Completed

Conditions: Hormone Refractory Prostate Cancer
Recurrent Prostate Cancer

Interventions: Drug: cediranib maleate
Drug: dasatinib

First Posted Date: 2010-12-15

Last Posted Date: 2018-08-08

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 22

Registration Number: NCT01260688

Locations: 🇺🇸
Illinois CancerCare-Peoria, Peoria, Illinois, United States
🇨🇦
BCCA-Vancouver Cancer Centre, Vancouver, British Columbia, Canada
🇨🇦
University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada

and more 5 locations

Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers

Phase 2

Terminated

Conditions: Localized Unresectable Adult Primary Liver Cancer
Periampullary Adenocarcinoma
Adult Primary Cholangiocellular Carcinoma
Advanced Adult Primary Liver Cancer
Cholangiocarcinoma of the Extrahepatic Bile Duct
Cholangiocarcinoma of the Gallbladder
Recurrent Extrahepatic Bile Duct Cancer
Unresectable Extrahepatic Bile Duct Cancer
Unresectable Gallbladder Cancer
Recurrent Adult Primary Liver Cancer

Interventions: Drug: cediranib maleate
Drug: oxaliplatin
Drug: leucovorin calcium
Drug: fluorouracil

First Posted Date: 2010-10-27

Last Posted Date: 2017-03-29

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 14

Registration Number: NCT01229111

Locations: 🇺🇸
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States
🇺🇸
Lake University Ireland Cancer Center, Mentor, Ohio, United States
🇺🇸
UHHS-Chagrin Highlands Medical Center, Orange Village, Ohio, United States

and more 4 locations

Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer

Phase 1

Completed

Conditions: Refractory Differentiated Thyroid Gland Carcinoma
Refractory Thyroid Gland Follicular Carcinoma
Unresectable Thyroid Gland Carcinoma
Refractory Thyroid Gland Hurthle Cell Carcinoma
Refractory Thyroid Gland Papillary Carcinoma

Interventions: Drug: Cediranib
Drug: Cediranib Maleate
Other: Laboratory Biomarker Analysis
Drug: Lenalidomide

First Posted Date: 2010-09-23

Last Posted Date: 2021-07-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 127

Registration Number: NCT01208051

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

and more 30 locations

Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer

Phase 2

Completed

Conditions: Endometrial Adenosquamous Carcinoma
Endometrial Serous Adenocarcinoma
Endometrial Clear Cell Adenocarcinoma
Endometrial Adenocarcinoma
Recurrent Uterine Corpus Carcinoma

Interventions: Drug: Cediranib Maleate
Other: Laboratory Biomarker Analysis

First Posted Date: 2010-05-28

Last Posted Date: 2019-08-08

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 53

Registration Number: NCT01132820

Locations: 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸
Cancer Center of Kansas-Independence, Independence, Kansas, United States
🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States

and more 84 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy